H.C. Wainwright Reiterates Neutral Rating on Xenetic Biosciences (XBIO)

H.C. Wainwright analyst Joseph Pantginis reiterated a Neutral rating on Xenetic Biosciences (NASDAQ: XBIO).

The analyst commented: "Following the 2022 acquisition of the DNase I platform from CLS Therapeutics (private) in 2022, preclinical work has been percolating in the background. As we approach SITC in November, plus other conferences, we expect important inflection point coming from more advanced preclinical models, which should solidify the rationale of the clinical path forward for DNase I and the elimination of NETs, in our belief. Below, we provide the up to date preclinical data and then expect two sets of important updates in November at: (1) SITC; and (2) AACR Special Conference: Tumor-Body Interactions. Maintain Neutral rating."

For an analyst ratings summary and ratings history on Xenetic Biosciences click here. For more ratings news on Xenetic Biosciences click here.

Shares of Xenetic Biosciences closed at $3.76 yesterday.

You May Also Be Interested In

• Correction: Kepler Cheuvreux Upgrades Siemens AG (SIE:GR) (SIEGY) to Hold
• HSBC Downgrades Stellantis NV (STLA:IM) (STLA) to Reduce
• Midera Food Processing and Centrus Energy to join S&P SmallCap 600